vs

Side-by-side financial comparison of AVADEL PHARMACEUTICALS PLC (AVDL) and California BanCorp \ CA (BCAL). Click either name above to swap in a different company.

AVADEL PHARMACEUTICALS PLC is the larger business by last-quarter revenue ($77.5M vs $45.9M, roughly 1.7× California BanCorp \ CA). California BanCorp \ CA runs the higher net margin — 35.8% vs 0.0%, a 35.8% gap on every dollar of revenue. On growth, AVADEL PHARMACEUTICALS PLC posted the faster year-over-year revenue change (54.9% vs 0.8%). California BanCorp \ CA produced more free cash flow last quarter ($56.9M vs $22.2M). Over the past eight quarters, AVADEL PHARMACEUTICALS PLC's revenue compounded faster (99.6% CAGR vs 44.7%).

Avadel Pharmaceuticals, is an Irish specialty pharmaceutical company that focuses on sleep disorder medicines. Avadel markets products in the hospital and primary care spaces. The company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.

Pacific Premier Bancorp, Inc. is an American bank holding company under the Bank Holding Company Act of 1956 headquartered in Irvine, California, US. Its principal business focuses on Pacific Premier Bank, which offers a range of financial services to individuals, businesses, and professionals. The bank operates numerous branches in California, Arizona, Nevada, and Washington.

AVDL vs BCAL — Head-to-Head

Bigger by revenue
AVDL
AVDL
1.7× larger
AVDL
$77.5M
$45.9M
BCAL
Growing faster (revenue YoY)
AVDL
AVDL
+54.1% gap
AVDL
54.9%
0.8%
BCAL
Higher net margin
BCAL
BCAL
35.8% more per $
BCAL
35.8%
0.0%
AVDL
More free cash flow
BCAL
BCAL
$34.7M more FCF
BCAL
$56.9M
$22.2M
AVDL
Faster 2-yr revenue CAGR
AVDL
AVDL
Annualised
AVDL
99.6%
44.7%
BCAL

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
AVDL
AVDL
BCAL
BCAL
Revenue
$77.5M
$45.9M
Net Profit
$20.0K
$16.4M
Gross Margin
Operating Margin
2.5%
48.8%
Net Margin
0.0%
35.8%
Revenue YoY
54.9%
0.8%
Net Profit YoY
100.8%
-2.1%
EPS (diluted)
$0.00
$0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AVDL
AVDL
BCAL
BCAL
Q4 25
$45.9M
Q3 25
$77.5M
$45.2M
Q2 25
$68.1M
$44.3M
Q1 25
$52.5M
$44.8M
Q4 24
$50.4M
$45.5M
Q3 24
$50.0M
$38.1M
Q2 24
$41.5M
$22.2M
Q1 24
$27.2M
$21.9M
Net Profit
AVDL
AVDL
BCAL
BCAL
Q4 25
$16.4M
Q3 25
$20.0K
$15.7M
Q2 25
$9.7M
$14.1M
Q1 25
$-4.9M
$16.9M
Q4 24
$-5.0M
$16.8M
Q3 24
$-2.6M
$-16.5M
Q2 24
$-13.8M
$190.0K
Q1 24
$-27.3M
$4.9M
Gross Margin
AVDL
AVDL
BCAL
BCAL
Q4 25
Q3 25
Q2 25
90.7%
Q1 25
89.4%
Q4 24
90.5%
Q3 24
87.7%
Q2 24
93.3%
Q1 24
94.4%
Operating Margin
AVDL
AVDL
BCAL
BCAL
Q4 25
48.8%
Q3 25
2.5%
48.3%
Q2 25
13.0%
45.3%
Q1 25
-5.7%
52.8%
Q4 24
-6.5%
52.2%
Q3 24
-0.7%
-59.1%
Q2 24
-30.7%
1.3%
Q1 24
-95.8%
33.1%
Net Margin
AVDL
AVDL
BCAL
BCAL
Q4 25
35.8%
Q3 25
0.0%
34.7%
Q2 25
14.2%
31.8%
Q1 25
-9.4%
37.6%
Q4 24
-10.0%
37.7%
Q3 24
-5.2%
-43.2%
Q2 24
-33.3%
0.9%
Q1 24
-100.6%
22.5%
EPS (diluted)
AVDL
AVDL
BCAL
BCAL
Q4 25
$0.50
Q3 25
$0.00
$0.48
Q2 25
$0.10
$0.43
Q1 25
$-0.05
$0.52
Q4 24
$-0.04
$0.54
Q3 24
$-0.03
$-0.59
Q2 24
$-0.14
$0.01
Q1 24
$-0.30
$0.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AVDL
AVDL
BCAL
BCAL
Cash + ST InvestmentsLiquidity on hand
$91.6M
$399.9M
Total DebtLower is stronger
$33.8M
Stockholders' EquityBook value
$98.2M
$576.6M
Total Assets
$199.4M
$4.0B
Debt / EquityLower = less leverage
0.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AVDL
AVDL
BCAL
BCAL
Q4 25
$399.9M
Q3 25
$91.6M
$559.2M
Q2 25
$81.5M
$430.1M
Q1 25
$66.5M
$439.2M
Q4 24
$73.8M
$388.2M
Q3 24
$65.8M
$614.4M
Q2 24
$71.4M
$104.7M
Q1 24
$88.8M
$86.5M
Total Debt
AVDL
AVDL
BCAL
BCAL
Q4 25
$33.8M
Q3 25
$33.4M
Q2 25
$52.9M
Q1 25
$70.3M
Q4 24
$69.7M
Q3 24
$69.1M
Q2 24
$42.9M
Q1 24
$44.9M
Stockholders' Equity
AVDL
AVDL
BCAL
BCAL
Q4 25
$576.6M
Q3 25
$98.2M
$564.7M
Q2 25
$90.7M
$547.6M
Q1 25
$74.1M
$531.4M
Q4 24
$73.8M
$511.8M
Q3 24
$74.7M
$498.1M
Q2 24
$70.3M
$293.2M
Q1 24
$78.4M
$292.5M
Total Assets
AVDL
AVDL
BCAL
BCAL
Q4 25
$4.0B
Q3 25
$199.4M
$4.1B
Q2 25
$187.2M
$4.0B
Q1 25
$167.9M
$4.0B
Q4 24
$164.2M
$4.0B
Q3 24
$158.3M
$4.4B
Q2 24
$157.5M
$2.3B
Q1 24
$167.9M
$2.3B
Debt / Equity
AVDL
AVDL
BCAL
BCAL
Q4 25
0.06×
Q3 25
0.06×
Q2 25
0.10×
Q1 25
0.13×
Q4 24
0.14×
Q3 24
0.14×
Q2 24
0.15×
Q1 24
0.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AVDL
AVDL
BCAL
BCAL
Operating Cash FlowLast quarter
$22.2M
$57.3M
Free Cash FlowOCF − Capex
$22.2M
$56.9M
FCF MarginFCF / Revenue
28.7%
124.1%
Capex IntensityCapex / Revenue
0.0%
0.8%
Cash ConversionOCF / Net Profit
1110.25×
3.49×
TTM Free Cash FlowTrailing 4 quarters
$93.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AVDL
AVDL
BCAL
BCAL
Q4 25
$57.3M
Q3 25
$22.2M
$16.0M
Q2 25
$12.7M
$13.4M
Q1 25
$-8.2M
$7.0M
Q4 24
$7.9M
$50.3M
Q3 24
$-6.9M
$18.3M
Q2 24
$-18.2M
$309.0K
Q1 24
$-29.7M
$8.1M
Free Cash Flow
AVDL
AVDL
BCAL
BCAL
Q4 25
$56.9M
Q3 25
$22.2M
$15.9M
Q2 25
$13.4M
Q1 25
$6.9M
Q4 24
$49.7M
Q3 24
$18.1M
Q2 24
$171.0K
Q1 24
$8.0M
FCF Margin
AVDL
AVDL
BCAL
BCAL
Q4 25
124.1%
Q3 25
28.7%
35.1%
Q2 25
30.2%
Q1 25
15.3%
Q4 24
109.2%
Q3 24
47.5%
Q2 24
0.8%
Q1 24
36.4%
Capex Intensity
AVDL
AVDL
BCAL
BCAL
Q4 25
0.8%
Q3 25
0.0%
0.2%
Q2 25
0.1%
Q1 25
0.2%
Q4 24
1.2%
Q3 24
0.0%
0.5%
Q2 24
0.6%
Q1 24
0.4%
Cash Conversion
AVDL
AVDL
BCAL
BCAL
Q4 25
3.49×
Q3 25
1110.25×
1.02×
Q2 25
1.31×
0.95×
Q1 25
0.41×
Q4 24
3.00×
Q3 24
Q2 24
1.63×
Q1 24
1.63×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons